


Buzduga M<sup>1</sup>, Meyrat B<sup>2</sup>, Estremadoyro V<sup>2</sup>, Alamo Maestre L<sup>3</sup>, Typaldou S.A<sup>4</sup>, Pitteloud N<sup>5</sup>, Phan-Hug F<sup>1</sup>.

<sup>1</sup>Pediatric Endocrinology, Diabetes and Obesity Unit, Lausanne University Hospital (CHUV), Switzerland; <sup>2</sup>Service of Pediatric Surgery, Lausanne University Hospital (CHUV), Switzerland; <sup>3</sup>Service of Radiology, Lausanne University Hospital (CHUV), Switzerland; <sup>4</sup>Service of Pediatric psychiatry, Lausanne University Hospital (CHUV), Switzerland; <sup>5</sup>Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital (CHUV), Switzerland.

## Background

Chimerism is characterised by the presence of two or more genetically distinct cell lines (originating from two or more zygotes) in the same individual. In situations when the sex of the fertilized eggs is disparate, it can lead to intersex phenotypes.



## Case report

A 17 year-old adolescent from Togo presented at birth with perineoscrotal hypospadias. He was raised as a male and underwent urethroplasty at age 10. His twin sister was phenotypically normal and healthy. At 12 years he developed severe gynecomastia. He expressed male gender identity. Between 12-17 years he developed severe gynecomastia and periodic hematuria. He expressed male gender identity. At 17 years he came to Switzerland for mastectomy.

## Evaluation by DSD team


**1. Clinical assessment:** A<sub>2</sub> PP<sub>4</sub>G<sub>4</sub>  
 Penis size: 6.5x2.5 cm  
 Testicular volume: 2ml

### 2. Biochemical analyses

|   |            |
|---|------------|
| LH (2-9 UI/l)                                 | 12.6       |
| FSH(2-12 UI/l)                                | 7.7        |
| Testosterone (9-32nmol/l for P4)              | <b>4.4</b> |
| CEstradiol (0.035-0.13nmol/l for P4)          | 0.39       |
| 17-OH hydroxyprogesterone (< 3 nmol/l)        | 1.7        |
| AMH (4.1-75.7 pmol/l)                         | 10.9       |
| Inhibine B (67-304 pg/ml for P <sub>4</sub> ) | 35.1       |

### 3. Imaging studies

MRI revealed small right testis, intraabdominal left ovary (2.8 x 2.7 cm) and presence of both an uterus (9.3 ml) and the proximal two thirds of a vagina.



**4. Karyotype test:** 46 XX [82], 46 XY [18]

**5. Diagnostic:** Chimeric ovotesticular DSD

## Management


**Surgery:** 2<sup>nd</sup> stage of Bracka's hypospadias surgery, bilateral mastectomy, laparotomy: left ovariectomy and hysterectomy, left testicular prosthesis.

## Follow up 3 month after surgery

A<sub>2</sub> PP<sub>5</sub>G<sub>4</sub>  
 Penis size: 7.0x2.8 cm  
 Testicular volume: 5ml


**Ovarian histopathology:**  
 normal ovarian tissue.

**Testicular ultrasonography:**  
 normal tissue, no focal lesions.



## Discussion

- Chimerism is a rare condition with few reported cases.
- Spontaneous fertility has been reported in both sexes.
- The functional testis induced spontaneous virilisation after ovariectomy.
- Post surgical inhibine B indicates low fertility potential.
- Evaluation of risk of gonadoblastoma:  
 For the moment: clinical observation has been chosen.  
 For the future: testosterone substitution is probably indicated (gonadectomy ?).



## Conclusions

- Chimerism can cause DSD with broad phenotypic spectrum including possibly functional ovary and testis.
- Surgery should be based on gender identity and not on sex of rearing. This argues for later intervention.
- One must consider gonadectomy for the risk of gonadoblastoma vs conservative approach (spontaneous virilisation/potential fertility).